Revolution Medicines (RVMD) Profit After Tax (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Profit After Tax of -$453.8 million for Q1 2026, down 112.64% year-over-year from $3.6 billion in Q1 2025, and down 25.03% quarter-over-quarter from -$363.0 million in Q4 2025.
Revolution Medicines (RVMD) Profit After Tax (2019 - 2026) Analysis & Trends
Revolution Medicines' Profit After Tax history runs 8 years deep, the most recent figure standing at -$453.8 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 112.64% year-over-year to -$453.8 million; the TTM figure through Mar 2026 stood at -$1.4 billion (down 96.38% YoY), while the FY2025 annual figure was -$1.1 billion, down 88.2% from the prior year.
- Profit After Tax for Q1 2026 stood at -$453.8 million, down from -$363.0 million in the prior quarter.
- The five-year high for Profit After Tax was -$56.5 million in Q4 2022, with the low at -$453.8 million in Q1 2026.
- The 5-year median for Profit After Tax is -$133.2 million (2024), against an average of -$168.6 million.
- The sharpest annual moves came in 2022 and 2023: Profit After Tax slipped 6.28% in 2022, then sank 181.76% in 2023.
- Revolution Medicines' Profit After Tax stood at -$56.5 million in 2022, then tumbled by 181.76% to -$159.2 million in 2023, then fell by 22.21% to -$194.6 million in 2024, then sank by 86.55% to -$363.0 million in 2025, then retreated by 25.03% to -$453.8 million in 2026.
- Business Quant data shows RVMD's Profit After Tax at -$453.8 million in Q1 2026, -$363.0 million in Q4 2025, and -$305.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -644.37 Mn |
| Mar 31, 2026 | -453.82 Mn |
| Dec 31, 2025 | -362.98 Mn |
| Sep 30, 2025 | -305.21 Mn |
| Jun 30, 2025 | -247.79 Mn |
| Mar 31, 2025 | -213.42 Mn |
| Dec 31, 2024 | -194.57 Mn |
| Sep 30, 2024 | -156.29 Mn |
| Jun 30, 2024 | -133.23 Mn |
| Mar 31, 2024 | -116.00 Mn |
| Dec 31, 2023 | -159.21 Mn |
| Sep 30, 2023 | -108.05 Mn |
| Jun 30, 2023 | -98.30 Mn |
| Mar 31, 2023 | -68.10 Mn |
| Dec 31, 2022 | -56.51 Mn |
| Sep 30, 2022 | -73.33 Mn |
| Jun 30, 2022 | -61.22 Mn |
| Mar 31, 2022 | -57.65 Mn |
| Dec 31, 2021 | -53.17 Mn |
| Sep 30, 2021 | -52.94 Mn |